BioMarin Pharmaceutical Given Average Recommendation of “Buy” by Brokerages (NASDAQ:BMRN)
Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) have earned a consensus rating of “Buy” from the seventeen brokerages that are covering the stock, ARN reports. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $82.46.
In other BioMarin Pharmaceutical news, EVP Henry J. Fuchs sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $65.00, for a total value of $650,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.
BioMarin Pharmaceutical (NASDAQ:BMRN) opened at 67.99 on Friday. BioMarin Pharmaceutical has a one year low of $55.04 and a one year high of $84.25. The stock has a 50-day moving average of $62.07 and a 200-day moving average of $65.27. The company’s market cap is $10.002 billion.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Wednesday, July 30th. The company reported ($0.23) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.41) by $0.18. The company had revenue of $191.70 million for the quarter, compared to the consensus estimate of $159.70 million. During the same quarter in the prior year, the company posted ($0.16) earnings per share. The company’s quarterly revenue was up 40.1% on a year-over-year basis. Analysts expect that BioMarin Pharmaceutical will post $-1.23 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Nomura raised their price target on shares of BioMarin Pharmaceutical from $77.00 to $82.00 in a research note on Thursday, July 31st. They now have a “neutral” rating on the stock. Analysts at Credit Suisse upgraded shares of BioMarin Pharmaceutical from a “neutral” rating to an “outperform” rating in a research note on Monday, June 9th. They now have a $73.00 price target on the stock, up previously from $61.74.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.